Provided by Tiger Trade Technology Pte. Ltd.

Myriad Genetics

4.27
-0.0200-0.47%
Volume:750.43K
Turnover:3.14M
Market Cap:398.02M
PE:-0.98
High:4.31
Open:4.27
Low:4.11
Close:4.29
52wk High:15.18
52wk Low:3.76
Shares:93.21M
Float Shares:85.72M
Volume Ratio:1.04
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3589
EPS(LYR):-1.4051
ROE:-72.52%
ROA:-5.67%
PB:1.07
PE(LYR):-3.04

Loading ...

Myriad Genetics Inc expected to post a loss of 1 cent a share - Earnings Preview

Reuters
·
Feb 21

Myriad Genetics Publishes Clinical Chemistry Validation of FirstGene Multiple Prenatal Screen

Reuters
·
Feb 19

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

GlobeNewswire
·
Feb 17

Myriad Genetics management to meet with BTIG

TIPRANKS
·
Feb 04

Myriad Genetics to Launch Precise MRD Test for Breast Cancer in March 2026

Reuters
·
Jan 27

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

GlobeNewswire
·
Jan 27

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Myriad Genetics (MYGN)

TIPRANKS
·
Jan 13

BRIEF-Myriad Genetics Announces Select Preliminary Fourth Quarter And Full Year 2025 Financial Results And Introduces Full Year 2026 Financial Guidance

Reuters
·
Jan 12

Myriad Genetics Projects 2025 Revenue Between $822 Million and $824 Million

Reuters
·
Jan 12

Myriad Genetics Inc - Full Year 2025 Revenues Expected Between $822 Mln and $824 Mln

THOMSON REUTERS
·
Jan 12

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
Jan 06

Myriad Genetics Unveils New Data on Precise MRD and MyRisk Tests at 2025 San Antonio Breast Cancer Symposium

Reuters
·
Dec 09, 2025

Myriad Genetics, Clairity, and MagView Launch Integrated AI and Genetic Breast Cancer Risk Platform

Reuters
·
Nov 26, 2025

Myriad Genetics Q3 EPS USD -0.29

Reuters
·
Nov 20, 2025

Myriad Genetics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Nov 12, 2025

Myriad Genetics to Join Wolfe Research and Piper Sandler Healthcare Conferences

Reuters
·
Nov 11, 2025

Stock Track | Myriad Genetics Soars 5% as MyRisk Cancer Test Expands to Include 15 New Actionable Genes

Stock Track
·
Nov 10, 2025

Myriad Genetics Expands MyRisk Hereditary Cancer Test with 15 New Clinically Actionable Genes

Reuters
·
Nov 10, 2025

Myriad Genetics Inc: Adds 15 Clinically Actionable Genes to Myrisk Hereditary Cancer Test

THOMSON REUTERS
·
Nov 10, 2025

Stock Track | Myriad Genetics Soars 5.02% Pre-market on Unveiling of 11 New Genetic Testing Studies

Stock Track
·
Nov 06, 2025